STOCK TITAN

Provectus Biopharms (PVCT) Stock Price, News & Analysis

PVCT OTC
Published by Stock Titan Data refreshed

Price Move History

Daily moves over 5%
65 252 sessions, November 18, 2025 to November 18, 2026
Largest daily move
-19.7% close of November 25, 2025
1-year change
-36.8% closing prices, November 18, 2025 to November 18, 2026
1-month change
-10.3% closing prices, October 16, 2026 to November 18, 2026

Company Description

Provectus Biopharmaceuticals, Inc. (PVCT) is a clinical-stage biotechnology company focused on developing immunotherapy medicines based on a class of bioactive synthetic small molecules known as halogenated xanthenes. The company’s lead molecule is rose bengal sodium (RBS), described as a first-in-class synthetic small molecule and active pharmaceutical ingredient that serves as the foundation for multiple therapeutic candidates across oncology, dermatology, ophthalmology, wound healing, hematology, infectious diseases, and tissue repair research programs.

Core science and medical platform

According to company disclosures, Provectus’s medical science platform centers on rose bengal sodium and other halogenated xanthenes as immuno-catalysts. These small molecules are investigated for their ability to modulate immune responses and influence disease processes in different tissues. The platform includes:

  • Clinical development programs in oncology, dermatology, and ophthalmology.
  • In vivo proof-of-concept programs in oncology, hematology, full-thickness cutaneous wound healing, and canine cancers.
  • In vitro discovery programs in infectious diseases, tissue regeneration and repair, and proprietary targets.

Information about the company’s clinical trials is reported to be available through the National Institutes of Health registry, ClinicalTrials.gov, reflecting its focus on formal clinical and preclinical evaluation of its investigational agents.

PV-10 and rose bengal sodium-based immunotherapy

A central investigational drug in Provectus’s pipeline is PV-10, which is formulated from the company’s pharmaceutical-grade rose bengal sodium active pharmaceutical ingredient. PV-10 is described in company news as an investigational cancer immunotherapy and is being studied in multiple settings:

  • Intratumoral PV-10 in solid tumors: Preclinical research at Moffitt Cancer Center in models of head and neck squamous cell carcinoma reported that PV-10 can trigger immunogenic cell death via endoplasmic reticulum stress and apoptosis, supporting potential future clinical development in locally recurrent head and neck squamous cell carcinoma.
  • Bladder cancer models: A preclinical study in an orthotopic bladder cancer model is evaluating PV-10 in different treatment arms, including oral and intravesical monotherapy and combination with an anti-PD-1 checkpoint inhibitor. The study is designed to generate translational data that could inform dose and route of administration decisions for potential future clinical trials.

These activities position PV-10 as a key application of Provectus’s rose bengal sodium platform in oncology, with research exploring both site-specific and systemic administration approaches in solid tumor and hematologic cancer contexts.

PV-10 as a potential vaccine adjuvant and immune system activator

Provectus has also highlighted independent preclinical research from the University of Calgary’s Cumming School of Medicine that examined PV-10 as an immune system activator in the context of vaccination. The published work reported that PV-10, as a formulation of pharmaceutical-grade rose bengal sodium, can:

  • Stabilize STING (stimulator of interferon genes) dimerization, a key step in innate immune activation.
  • Upregulate pro-inflammatory cytokines and chemokines important for adaptive immune responses.
  • Increase IFN-gamma secretion by antigen-primed T cells.

According to the company’s summary of this research, these findings suggest that PV-10 may function as a differentiated immune enhancer that works through a natural immune pathway. The research proposes that PV-10 could potentially serve as an alternative to traditional vaccine adjuvants and may have relevance in infectious disease, oncology vaccines, and preparedness applications, including for individuals who do not respond adequately to existing vaccines.

Dermatology and wound healing research

Provectus reports non-clinical work using its pharmaceutical-grade rose bengal sodium in full-thickness cutaneous wound models. Research presented at the Society for Investigative Dermatology annual meeting described topical application of low-concentration RBS to full-thickness wounds. In that work, the investigators reported:

  • No toxicity or mortality and no observed adverse effect level at the highest tested dose.
  • Reduced transepidermal water loss, suggesting improvement in skin barrier function.
  • Increased erythema and vascularity in early stages, consistent with blood flow and granulation tissue formation.
  • Accelerated wound closure, increased collagen density, and reduced angiogenesis after wound closure, which the researchers associated with tissue regeneration and fibrosis prevention.

This research forms part of Provectus’s broader exploration of rose bengal sodium in dermatology and wound healing, alongside its oncology and ophthalmology programs.

Ophthalmology and the VisiRose spinoff

Provectus has disclosed that it launched VisiRose, Inc. as a founded entity focused on ophthalmology applications of rose bengal sodium. VisiRose is described as a privately held, clinical-stage biotechnology company associated with the University of Miami and Provectus. Its initial focus is on commercializing Rose Bengal Photodynamic Antimicrobial Therapy (RB-PDAT) for infectious keratitis and other serious eye infections, using Provectus’s pharmaceutical-grade RBS and a light-based medical device developed at the Bascom Palmer Eye Institute’s Ophthalmic Biophysics Center.

RB-PDAT is characterized as a non-invasive investigational treatment designed to address eye infections caused by bacteria, fungi, and parasites, including multidrug-resistant organisms. VisiRose’s disclosed activities include preparing regulatory submissions such as a pre-investigational new drug meeting and investigational new drug application for eye drug candidates, as well as manufacturing initial clinical supply and pursuing grant funding. This ophthalmology-focused entity illustrates how Provectus’s rose bengal sodium platform is being extended into specialized therapeutic areas.

Pipeline breadth and research areas

Across its various disclosures, Provectus describes a pipeline that spans multiple disease areas and stages of development. Key areas include:

  • Oncology: Clinical programs and preclinical studies involving intratumoral and systemic use of PV-10 and related agents in solid tumors and hematologic cancers.
  • Dermatology: Development work in skin disease and wound healing, including full-thickness cutaneous wound models.
  • Ophthalmology: Rose bengal sodium-based investigational therapies for eye infections and other ocular conditions, including through VisiRose.
  • Hematology: In vivo proof-of-concept programs exploring hematologic applications.
  • Infectious diseases and tissue repair: In vitro discovery programs examining infectious disease targets, tissue regeneration and repair, and other proprietary targets.

All of these efforts are described as investigational, with safety and efficacy not yet established and subject to regulatory review. The company notes that there is no guarantee that its agents will receive health authority approval or become commercially available for the uses being investigated.

Corporate and trading profile

Provectus Biopharmaceuticals, Inc. is identified in its news releases as a clinical-stage biotechnology company whose common stock trades on the OTCQB market under the ticker symbol PVCT. The company references regular investor communications such as conference calls, investor webinars, and annual stockholder meetings, and indicates that proxy materials and annual reports are filed with the U.S. Securities and Exchange Commission and made available to stockholders.

How Provectus fits within pharmaceutical preparation manufacturing

Within the broader pharmaceutical preparation manufacturing and biotechnology landscape, Provectus presents itself as a company concentrating on small molecule immunotherapy rather than large biologics. Its approach is built around halogenated xanthenes, particularly rose bengal sodium, as a modular platform that can be formulated for different routes of administration and disease targets. The company’s activities, as described in its communications, emphasize mechanistic research (such as STING-pathway activation and immunogenic cell death), translational preclinical work, and early-stage clinical development.

Key points for PVCT stock research

For those researching PVCT stock, available company materials highlight:

  • A focus on immunotherapy medicines derived from halogenated xanthenes, led by rose bengal sodium.
  • Clinical and preclinical programs in oncology, dermatology, ophthalmology, wound healing, hematology, infectious diseases, and tissue repair.
  • PV-10 as a lead investigational drug in cancer and as a potential immune system activator in vaccination research.
  • The creation of VisiRose to advance ophthalmology applications of rose bengal sodium.
  • Ongoing reliance on clinical trials and regulatory processes, with explicit caution that safety, efficacy, and commercial outcomes are not assured.

These elements frame Provectus Biopharmaceuticals as a clinical-stage, research-driven company whose value proposition is closely tied to the progress and results of its rose bengal sodium-based programs.

Stock Performance

$0.0437
-0.05%
-0.0000
Last updated: at
-36.8%
Performance 1 year
$18.4M

Provectus Biopharms (PVCT) closed at $0.0437 on November 18, 2026. Over the past 12 months, the price has lost 36.8%.

See what a $1,000 investment in PVCT would be worth today

Average down calculator for PVCT

PVCT Metrics & Rankings

Price returns through November 18, 2026. Month and year figures include the first trading day. Ranking links may use different dates.

Latest News

Provectus Biopharms has 10 recent news articles. Of the recent coverage, 5 articles coincided with positive price movement and 5 with negative movement. View all PVCT news →

Financial Highlights

Provectus Biopharms generated $336K in revenue in FY2025. Diluted earnings per share stood at -$0.01. The company generated -$3.3M in operating cash flow. The current ratio was 0.08, measuring current assets divided by current liabilities.

$336K
Revenue (FY2025)
-$3.3M
Operating Cash Flow
—
Net Income (FY2025)

Upcoming Events

No upcoming events scheduled for PVCT.

Short Interest History

Last 12 Months

Short interest in Provectus Biopharms (PVCT) currently stands at 801.2 thousand shares, representing 0.2% of the float. Since November 2025, short interest has increased by 160134.8%.

Days to Cover History

Last 12 Months

Days to cover for Provectus Biopharms (PVCT) currently stands at 4.6 days, down 20.9% from the previous period. The ratio is the reported short interest divided by the average daily trading volume. Since November 2025, the figure has increased by 357%. Across the settlements charted above, it has ranged from 1.0 to 5.8 days.

PVCT Company Profile & Sector Positioning

Provectus Biopharms (PVCT) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the OTC.

Investors comparing PVCT often look at related companies in the same sector, including Resverlogix Corp (RVXCF), Biomind Labs Inc (BMNDF), Sharp Therapeutics Corp (SHRXF), Medicenna Thera Corp (MDNAF), and Biophytis SA (BPTSY). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate PVCT's relative position within its industry.

Frequently Asked Questions

The current stock price of Provectus Biopharms (PVCT) is $0.0437 as of November 18, 2026.

The market cap of Provectus Biopharms (PVCT) is approximately $18.4M. Learn more about what market capitalization means .

The FY2025 revenue of Provectus Biopharms (PVCT) is $336K, from its most recent completed fiscal year.

The diluted earnings per share (EPS) of Provectus Biopharms (PVCT) is -$0.01 for FY2025, its most recent completed fiscal year. Learn more about EPS .

The operating cash flow of Provectus Biopharms (PVCT) is -$3.3M for FY2025, its most recent completed fiscal year. Learn about cash flow.

The current ratio of Provectus Biopharms (PVCT), current assets divided by current liabilities, was 0.08 at the end of FY2025, its most recent completed fiscal year. Learn about liquidity ratios.

Provectus Biopharmaceuticals, Inc. is a clinical-stage biotechnology company developing immunotherapy medicines based on bioactive synthetic small molecules called halogenated xanthenes. Its lead molecule, rose bengal sodium, underpins clinical programs in oncology, dermatology, and ophthalmology, along with proof-of-concept and discovery work in hematology, wound healing, infectious diseases, and tissue repair.

PV-10 is Provectus’s lead investigational drug formulated from its pharmaceutical-grade rose bengal sodium active pharmaceutical ingredient. It is being studied as a cancer immunotherapy, including intratumoral use in solid tumors and in preclinical models such as head and neck squamous cell carcinoma and bladder cancer, and has also been evaluated as an immune system activator in vaccine-related research.

Provectus uses pharmaceutical-grade rose bengal sodium as the core active pharmaceutical ingredient in several investigational applications. These include PV-10 for oncology, topical formulations for full-thickness cutaneous wound models, and rose bengal-based approaches in ophthalmology through its founded entity VisiRose. The company also supports in vitro discovery work in infectious diseases and tissue regeneration using this molecule.

According to company disclosures, Provectus’s pipeline spans oncology, dermatology, and ophthalmology in clinical development. It also includes in vivo proof-of-concept programs in oncology, hematology, full-thickness cutaneous wound healing, and canine cancers, as well as in vitro discovery programs in infectious diseases, tissue regeneration and repair, and proprietary targets.

Independent preclinical research from the University of Calgary, as cited by Provectus, reported that PV-10 can stabilize STING dimerization, upregulate pro-inflammatory cytokines and chemokines, and increase IFN-gamma secretion by antigen-primed T cells. These findings suggest that PV-10 may activate the body’s natural STING pathway and enhance immune responses in vaccination models.

Provectus has reported non-clinical data from the University of Texas Medical Branch at Galveston on topical rose bengal sodium in full-thickness cutaneous wound models. The research described no observed toxicity at tested doses and reported findings such as reduced transepidermal water loss, increased vascularity and collagen density, accelerated wound closure, and reduced angiogenesis after closure, which the investigators associated with wound healing and tissue regeneration.

Company news releases state that Provectus Biopharmaceuticals, Inc. trades on the OTCQB market under the ticker symbol PVCT. The company also references filings with the U.S. Securities and Exchange Commission and regular investor communications such as conference calls and annual stockholder meetings.

No. Provectus describes itself as a clinical-stage company, and its agents and uses are under investigation. The company notes that the safety and efficacy of these agents have not been established and that there is no guarantee they will receive health authority approval or become commercially available for the uses being investigated.

Provectus states that information about its clinical trials can be found at the National Institutes of Health registry, ClinicalTrials.gov. This registry provides listings and details for registered clinical studies involving the company’s investigational agents.